CD69 and adenocarcinoma: The activation marker CD69 appeared to be slightly, but not significantly, elevated on CD3+ T cells of patients with squamous cell (p = 0.81) and adenocarcinoma (p = 0.197) patients compared to healthy controls (Figure 4B).